Five years communicating almost exclusively in monosyllables. That was the condition of an 80-year-old woman with a decade of advanced Alzheimer’s when her caregivers decided to give her a single 5-gram oral dose of Enigma-strain psilocybin mushrooms.
Approximately 19 hours after the dose, the patient began speaking spontaneously in autobiographical sentences. In the days and weeks that followed, she regained urinary continence, improved her mobility, was able to dress herself, and showed greater emotional reciprocity with those around her. One month later she received a second 3-gram dose; the records documented greater verbal expressiveness, humor, and agility. The case was published in the scientific journal Frontiers in Neuroscience in May 2026.
The researchers themselves warned that the underlying neurodegeneration was not reversed and that the improvements were temporary. It is a single case, not a clinical trial, and the results are not generalizable. But this is the fact specialists cannot ignore: there is currently no approved medication that produces such rapid and multidimensional improvements in advanced Alzheimer’s. Psilocybin was already being studied for depression, addiction, and PTSD — and now it has neuroscience looking in a direction that years ago would have seemed unthinkable.